AIDS Healthcare Foundation v. Gilead Sciences, Inc.

  1. August 13, 2018

    Fed. Circ. Wrong On HIV Drug Patent Challenge, Justices Hear

    A health care group told the U.S. Supreme Court it was improperly barred by the Federal Circuit from challenging a patent for an HIV drug because it had not filed an Abbreviated New Drug Application for a generic version of the drug, according to a petition for certiorari related to its request for declaratory judgment ruling the patents are invalid.

  2. May 11, 2018

    Fed. Circ. Affirms Dismissal Of AIDS Drug Antitrust Case

    A Federal Circuit panel affirmed Friday a California district court's ruling that AIDS Healthcare Foundation Inc. can't invalidate five patents for HIV treatments or support antitrust claims against Gilead Sciences Inc. because the foundation could not show it had any connection to the intellectual property that would warrant the action.